Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 15/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876174 | 0.85 | CDKN1A (0.53) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1880531 | 0.83 | CDKN1A (0.57) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1877962 | 0.83 | CDKN1A (0.55) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1884314 | 0.83 | CDKN1A (0.56) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1874348 | 0.82 | CDKN1A (0.59) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1878758 | 0.82 | CDKN1A (0.54) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1883241 | 0.82 | CDKN1A (0.52) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1875640 | 0.82 | CDKN1A (0.52) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1874038 | 0.81 | CDKN1A (0.51) | CDKN1AKDM4EBRAFTLR8 | |
| SCHEMBL1873231 | 0.81 | CDKN1A (0.51) | CDKN1AKDM4EBRAFTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | claimed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | claimed |
| CN-100393721-C | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INT (ES) | 2008-06-11 | — | — | CN | claimed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | claimed |
| CN-1829719-A | N- [ 3- (3-substituted-pyrazolo [1, 5-a ] pyrimidin-7-yl) phenyl ] -sulfonamides, compositions thereof, and related methods | FERRER INT (ES) | 2006-09-06 | — | — | CN | claimed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | disclosed |
| CN-100393721-C | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INT (ES) | 2008-06-11 | — | — | CN | disclosed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| CN-1829719-A | N- [ 3- (3-substituted-pyrazolo [1, 5-a ] pyrimidin-7-yl) phenyl ] -sulfonamides, compositions thereof, and related methods | FERRER INT (ES) | 2006-09-06 | — | — | CN | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | GABRA2, GABRA1, GABRA3 | CDKN1A 1593/4885KDM4E 3264/4885BRAF 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.